SEC
SlamSEC
SearchBrowseEarnings

Evotec SE

Nasdaq:EVOOTC:EVOTF
Pharmaceutical Preparations·HAMBURG
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

All Filings(171 total)

TypeDateAccessionPeriodSize
6-K
Mar 10, 2026
0001104659-26-025429FORM 6-K
Mar 10, 2026
72.7 KB
SCHEDULE 13G/A
Feb 17, 2026
0001388325-26-000009
—
6.8 KB
SCHEDULE 13G
Jan 16, 2026
0001019056-26-000009
—
18.6 KB
6-K
Jan 16, 2026
0001104659-26-004318FORM 6-K
Jan 16, 2026
1.7 MB
6-K
Jan 13, 2026
0001104659-26-003082FORM 6-K
Jan 13, 2026
1.0 MB
6-K
Jan 8, 2026
0001104659-26-001983FORM 6-K
Jan 8, 2026
587.0 KB
6-K
Jan 6, 2026
0001104659-26-001075FORM 6-K
Jan 6, 2026
1.0 MB
6-K
Jan 2, 2026
0001104659-26-000054FORM 6-K
Jan 2, 2026
1.1 MB
6-K
Jan 2, 2026
0001104659-26-000053FORM 6-K
Jan 1, 2026
50.2 KB
6-K
Dec 8, 2025
0001104659-25-119055FORM 6-K
Dec 8, 2025
68.1 KB
SCHEDULE 13G/A
Nov 14, 2025
0001388325-25-000029
—
6.8 KB
6-K
Nov 6, 2025
0001104659-25-107536FORM 6-K
Nov 6, 2025
16.4 KB
6-K
Nov 5, 2025
0001104659-25-106581FORM 6-K
Nov 5, 2025
411.5 KB
6-K
Nov 5, 2025
0001104659-25-106576FORM 6-K
Nov 4, 2025
75.1 KB
SCHEDULE 13D/A
Oct 29, 2025
0001193125-25-256684
—
13.2 KB
6-K
Aug 13, 2025
0001104659-25-077175FORM 6-K
Aug 13, 2025
1.0 MB
6-K
Jul 30, 2025
0001104659-25-071895FORM 6-K
Jul 30, 2025
75.9 KB
6-K
Jul 21, 2025
0001104659-25-069147FORM 6-K
Jul 21, 2025
64.9 KB
6-K
Jun 3, 2025
0001104659-25-055821FORM 6-K
Jun 3, 2025
30.3 KB
6-K
May 6, 2025
0001104659-25-044714FORM 6-K
May 6, 2025
359.1 KB
20-F
Apr 17, 2025
0001104659-25-035638FORM 20-F
Dec 31, 2024
30.7 MB
6-K
Apr 17, 2025
0001104659-25-035630FORM 6-K
Apr 17, 2025
88.5 KB
6-K
Apr 17, 2025
0001104659-25-035623FORM 6-K
Apr 17, 2025
75.7 KB
6-K
Nov 29, 2024
0001654954-24-014998FORM 6-K
Nov 29, 2024
40.4 KB
6-K
Nov 22, 2024
0001104659-24-121952FORM 6-K
Nov 22, 2024
14.3 KB
25 filings shown

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.